维利西呱需要注意什么

Veliciguat is contraindicated in patients who are concurrently taking other soluble guanylate cyclase (sGC) stimulators; it is contraindicated in pregnancy. Take a pregnancy test before starting treatment. Advise females of reproductive potential to use effective contraception during treatment with veliciguat and for at least one month after the final dose.

No dose adjustment of veliciguat is recommended in patients with an estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73m2 who are not receiving dialysis. Veliciguat treatment initiation or dialysis has not been studied in patients with eGFR <15mL/min/1.73m2).

No dose adjustment of veliciguat is recommended in patients with mild or moderate hepatic impairment (e.g., Child-Pugh A or B). Veliciguat has not been studied in patients with severe hepatic impairment (eg, Child-Pugh C).

It is contraindicated in patients who are breastfeeding or planning to breastfeed. It is unknown whether veliciguat passes into breast milk. Do not breastfeed if you are taking vericiguat.

Take once daily with food. Viriciguat should be swallowed whole. If you are unable to swallow the tablet whole, you can crush the vericiguat tablet and mix it with water before taking it. Veliciguat must be taken with food and the starting dose is 2.5 mg once daily. The dose is doubled every 2 weeks or so, and can be increased to a maximum of 10 mg, once a day, in order to achieve maximum efficacy.

The potential risk of hypotension increases when veliciguat is used in combination with antihypertensive drugs, nitrate drugs, and sildenafil. Once a patient develops symptoms of hypotension, it is recommended to temporarily reduce the dose or discontinue Vericiguat. In addition, sildenafil and vericiguat act on the same pathway, and adverse reactions may be superimposed, so the combined use of sildenafil and vericiguat is not recommended.

Veliciguat is indicated for the treatment of symptomatic chronic heart failure with reduced ejection fraction (ejection fraction <45%) in adult patients with decompensated heart failure who are stable after intravenous therapy to reduce the risk of hospitalization for heart failure or the need for emergency intravenous diuretic therapy. Vericiguat can improve myocardial and vascular function, restore the weakened myocardium to strong blood-pumping ability, and achieve the effect of improving heart failure by dilating systemic and pulmonary blood vessels and reducing heart beating resistance. It is recommended that patients take medication as directed by their doctor and receive symptomatic treatment.

Recommended related articles: